Brief: Standard Biotools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The Somascan® Platform For Translational Medicine Research
03/04/2024 21:13
April 3 (Reuters) - Standard BioTools Inc LAB.O :
* STANDARD BIOTOOLS ANNOUNCES MULTI-YEAR STRATEGIC
ENGAGEMENT WITH
BRISTOL MYERS SQUIBB FOR USE OF THE SOMASCAN® PLATFORM FOR
TRANSLATIONAL MEDICINE RESEARCH
Source text for Eikon: ID:nGNX7Z5tSn
Further company coverage: LAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Standard BioTools
See all newsBrief: Standard Biotools Announces Agreement To Sell Microfluidics Business To Archimed
Brief: Standard Biotools Provides Update On Sale Of Mass Cytometry Business
Standard BioTools Inc. reports results for the quarter ended June 30 - Earnings Summary
Standard BioTools Q2 revenue falls on consumables weakness
Brief: Standard BioTools Q2 EPS USD -0.07